anti-Nipah_300
| anti-Nipah_ID | anti-Nipah_300 |
| anti-Nipah Drug | 3-[(5Z)-4-oxo-5-[(5-phenylfuran-2-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-3-yl]propyl 4-{2-oxo-hexahydro-1H-thieno[3,4-d]imidazol-4-yl}butanoate |
| Nipah virus strain | NiV (NiV-pVSV) |
| Approaches used to test anti-Nipah activity | Experimental |
| Methods used to test anti-Nipah activity | in-vitro |
| Models used to test anti-Nipah activity | Vero |
| Mode of infection to test anti-Nipah activity | Adsorption |
| Viral titer to test anti-Nipah activity | NA NA |
| Mode of Drug delivery for anti-Nipah activity | Culture |
| Time of Drug delivery for anti-Nipah activity | Pre Infection |
| Duration of Drug delivery for anti-Nipah activity | NA |
| Drug concentration used to test anti-Nipah activity | 1.77 μM |
| Assays used to test anti-Nipah activity | Plaque assay |
| anti-Nipah activity | Decrease [Inhibitory concentration (50 %)] |
| References | Benhur Lee, Michael E. Jung, Michael C. Wolf, Tinghu Zhang Novel antiviral agents for enveloped viruses WO2010044924A |
| Comments | The study documented a series of arylmethylidene rhodanine derivatives having broad- spectrum antiviral activity against enveloped viruses, including but not limited to f_loviruses, poxviruses, arenaviruses, bunyaviruses, paramyxoviruses, flaviviruses, influenza A, and HIV- 1. The compounds act via a novel mechanism to disrupt viral membranes and inhibit viral attachment, fusion, and/or entry into host cells. |